ABC transporters, atherosclerosis and inflammation

Area of Science:

• Cardiovascular Biology
• Lipid Metabolism
• Molecular Medicine

Background:

• Atherosclerosis is a major health burden driven by inflamed, lipid-laden arterial lesions.
• Reverse cholesterol transport (RCT) is a key physiological process that prevents atherosclerosis by removing lipids.
• Genetic defects in ATP-binding cassette (ABC) transporters, such as ABCA1 and ABCG5/G8, lead to inherited syndromes associated with premature atherosclerosis.

Purpose of the Study:

• To review the relationship between the lipid transport activities of ABC transporters and their anti-atherosclerotic effects.
• To explore how these transporters modulate inflammatory signaling pathways.
• To discuss the role of cell surface cholesterol modulation and lipid rafts in inflammation.

Main Methods:

• Review of existing literature on ABC transporters (ABCA1, ABCG5, ABCG8, ABCG1) and their roles in cholesterol and lipid transport.
• Analysis of genetic syndromes (Tangier disease, sitosterolemia) linked to ABC transporter mutations.
• Examination of studies investigating the impact of ABC transporters on inflammatory signaling and lipid rafts.

Main Results:

• Mutations in ABCA1 (Tangier disease) impair cholesterol efflux, leading to HDL deficiency and increased atherosclerosis risk.
• Mutations in ABCG5/G8 (sitosterolemia) hinder cholesterol and plant sterol excretion, also associated with atherosclerosis.
• ABCG1 and ABCA1 may reduce inflammation by modulating cell surface cholesterol and inhibiting lipid raft formation, which are platforms for immune receptors.

Conclusions:

• ABCA1, ABCG5/G8, and ABCG1 play critical roles in lipid homeostasis and possess anti-atherosclerotic properties.
• These transporters influence inflammation, partly by regulating cholesterol partitioning into lipid rafts.
• Further research into stimulating RCT pathways holds therapeutic potential for atherosclerosis.